Nonprofits collect a lot through forms (donations, volunteer sign-ups, event registrations, grant and program applications), ...

Paramount will exit its United International Pictures distribution joint venture with Universal as a condition for EU approval of its $111 billion takeover of Warner Bros. Discovery. The move is in ...

Viridian Therapeutics has scored FDA approval for Lumvoa to treat thyroid eye disease (TED), triggering competition with Amgen’s blockbuster Tepezza, the only other medicine on the market for the ...

Ted Pick, CEO of Morgan Stanley. Morgan Stanley now has approval from regulators to set up a digital asset-focused trust bank. Processing Content The company received conditional approval from the ...

Regulatory officials in Brussels are expected to greenlight Paramount’s $111 billion takeover of Warner Bros. Discovery, according to a Financial Times report, following its approval earlier this ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. The June 16-20 American Research Group survey found that 66 percent of ...

A new Reuters/Ipsos poll released June 15 puts President Donald Trump's approval rating a smidge higher than the outlet's last survey, at 36%, crediting a slight easing of Americans' affordability ...

A record-high number of Americans say they disapprove of President Donald Trump’s time in the White House, according to the latest Economist/YouGov poll. The poll, released June 2, showed that about ...

On Thursday, Anthropic released Opus 4.8, the newest version of its most advanced publicly available model. The model is available everywhere, with standard pricing at the same level as the previous ...

With six months to go until the midterm elections, President Donald Trump's poll numbers remain underwater. The two-month-long war with Iran, which public opinion surveys indicate is unpopular with ...

Earlier this year, when the FDA asked Amgen to pull its rare disease drug Tavneos from the market, the California drugmaker denied the request. Now, the U.S. regulator is applying more pressure. The ...